Key result
Atazanavir use is linked to ~89% lower odds of prolonged QTc in asymptomatic HIV patients.
Why the study?
The prevalence of prolonged QTc interval and its associated factors in asymptomatic HIV-infected patients were not well characterized.
Cohort (n=194)
Odds Ratio: 0.11 (95% CI 0.02–0.5)
p-value: p=0.008
Prolonged QTc is relatively common (12.4%) in asymptomatic HIV-infected patients and is associated with hyperlipidemia and diastolic dysfunction, whereas atazanavir use may be protective.
Alerts clinicians to QTc screening in asymptomatic HIV with hyperlipidemia or diastolic dysfunction; leaves open atazanavir's protective association.
We aimed to determine the prevalence of a prolonged QTc interval in HIV-infected patients and its related factors through an observational study of a cohort of asymptomatic HIV-infected outpatients. All patients underwent a standard 12-lead electrocardiogram and a transthoracic echocardiogram. Prolonged QTc was considered if it was >440 ms in men and >450 ms in women. Epidemiological, clinical, and laboratory data were collected and the patients completed a questionnaire about cardiovascular risk factors. The analysis of the potential risk factors for prolonged QTc was done by multivariate logistic regression. The study included 194 patients, 84% men, with a mean age of 46.3 years. The mean duration of HIV infection was 122.6 months and 27.8% had AIDS. Antiretroviral therapy was being taken by 185 (96.4%) patients, and 92.4% of them had an undetectable viral load. The mean CD4 lymphocyte count was 553/mm(3). A total of 24 (12.4%) patients had a prolonged QTc interval, with a mean QTc of 456 ms. The factors associated with a prolonged QTc were hyperlipidemia (OR 3.7, 95% CI: 1.3-10.3; p=0.01) and diastolic dysfunction (OR 6.7, 95% CI: 2.4-18.3; p=0.0001), while the use of atazanavir was associated with a lower likelihood of having a prolonged QTc (OR 0.11, 95% CI: 0.02-0.5; p=0.008). A prolonged QTc syndrome was not uncommon in this cohort of asymptomatic HIV-infected patients with good immunovirological control. It was associated with hyperlipidemia and diastolic dysfunction. The use of atazanavir, compared with other protease inhibitors, was associated with a lower likelihood of having a prolonged QTc.
No takes yet. Share an insight, caveat, or question.
Moreno et al. (2013) conducted a cohort in HIV infection (n=194). Atazanavir vs. Other protease inhibitors was evaluated on Prolonged QTc interval (>440 ms in men and >450 ms in women) (OR 0.11, 95% CI 0.02-0.5, p=0.008). In asymptomatic HIV-infected patients, prolonged QTc was present in 12.4% and was associated with hyperlipidemia and diastolic dysfunction, while atazanavir use was protective (OR 0.11; 95% CI 0.02-0.5).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: